KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Change in Accured Expenses (2016 - 2026)

Medtronic (MDT) has disclosed Change in Accured Expenses for 13 consecutive years, with $703.0 million as the latest value for Q1 2026.

  • Quarterly Change in Accured Expenses rose 27.82% to $703.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $289.0 million through Jan 2026, down 40.66% year-over-year, with the annual reading at $209.0 million for FY2025, 46.55% down from the prior year.
  • Change in Accured Expenses hit $703.0 million in Q1 2026 for Medtronic, up from -$182.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $703.0 million in Q1 2026 to a low of -$673.0 million in Q3 2023.
  • Historically, Change in Accured Expenses has averaged $110.5 million across 5 years, with a median of $177.0 million in 2023.
  • Biggest five-year swings in Change in Accured Expenses: soared 10250.0% in 2022 and later plummeted 357.82% in 2023.
  • Year by year, Change in Accured Expenses stood at $133.0 million in 2022, then crashed by 119.55% to -$26.0 million in 2023, then crashed by 296.15% to -$103.0 million in 2024, then tumbled by 76.7% to -$182.0 million in 2025, then soared by 486.26% to $703.0 million in 2026.
  • Business Quant data shows Change in Accured Expenses for MDT at $703.0 million in Q1 2026, -$182.0 million in Q4 2025, and -$598.0 million in Q3 2025.